

## Patterns of testing in the extensive Danish national SARS-CoV-2 test set-up

Mie Agermose Gram (MAG)<sup>1\*</sup>, Nina Steenhard (NS)<sup>2</sup>, Arie Sierra Cohen (ASC)<sup>2</sup>, Anne-Marie Vangsted (AMV)<sup>2</sup>, Kåre Mølbak (KM)<sup>3,4</sup>, Thøger Gorm Jensen (TGJ)<sup>5</sup>, Christian Holm Hansen (CHH)<sup>1</sup>, Steen Ethelberg (SE)<sup>1,6</sup>

<sup>1</sup> *Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, 5 Artillerivej, 2300 Copenhagen S, Denmark*

<sup>2</sup> *TestCentre Denmark, Statens Serum Institut, 5 Artillerivej, 2300 Copenhagen S, Denmark*

<sup>3</sup> *Division of Infectious Disease Preparedness, Statens Serum Institut, 5 Artillerivej, 2300 Copenhagen S, Denmark*

<sup>4</sup> *Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Grønnegaardsvej 15, 1870 Frederiksberg C, Denmark*

<sup>5</sup> *Department of Clinical Microbiology, Odense University Hospital, J.B. Winsløvs Vej 21, 2 5000 Odense C, Research Unit of Clinical Microbiology, University of Southern Denmark, Odense, Denmark.*

<sup>6</sup> *Department of Public Health, Global Health Section, University of Copenhagen, Øster Farimagsgade 5, 1014 Copenhagen K, Denmark.*

Contains 3 tables, 2 figures and supplementary material

Word count: Main text: 4290 words; abstract: 250 words.

\*Corresponding author: Mie Agermose Gram, Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, 5 Artillerivej, 2300 Copenhagen S, Denmark, T: +45 3268 3458, e-mail: miag@ssi.dk.

# Abstract

**Background:** The Danish national SARS-CoV-2 mass test system was among the most ambitious worldwide. We describe its set-up and analyse differences in patterns of testing per demography and time period in relation to the three waves of SARS-CoV-2 transmission in Denmark.

**Methods:** We included all reported PCR- and rapid antigen-tests performed between 27 February 2020 and 10 March 2022 among all residents aged 2 years or above. Descriptive statistics and Poisson regression models were used to analyse characteristics of individuals tested for SARS-CoV-2 using a national cohort study design.

**Results:** A total of 63.7 million PCR-tests and 60.0 million antigen-tests were performed in the study period, testing 91.1% and 79.2% of the Danish population at least once by PCR or antigen, respectively. Female sex, younger age, Danish heritage and living in the capital area were all factors positively associated with the frequency of PCR-testing. The association between COVID-19 vaccination and PCR-testing changed from negative to positive over time.

**Conclusion:** We provide details of the widely available, free-of-charge, national SARS-CoV-2 test system, which served to identify infected individuals, assist isolation of infectious individuals and contact tracing, and thereby mitigating the spread of SARS-CoV-2 in the Danish population. The test system was utilized by nearly the entire population at least once, and widely accepted across different demographic groups. However, demographic differences in the test uptake did exist and should be considered in order not to cause biases in studies related to SARS-CoV-2, e.g., studies of transmission and vaccine effectiveness.

**Keywords:** SARS-CoV-2 tests, COVID-19, SARS-CoV-2 RNA, SARS-CoV-2 antigen, RT-PCR, mass-testing

## Background

Diagnostic testing to identify individuals infected with the highly transmissible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is important to reduce the spread of the virus (1, 2). Public health experts have emphasized mass testing of as many individuals as possible – tracking infected individuals, and contact tracing – as an effective strategy to reduce the spread of the virus (1). During 2020-2022, Denmark set up one of the highest PCR mass testing capacities per capita in the world (3). The extensive, openly available, free-of-charge, national SARS-CoV-2 test system in Denmark, which was initiated at the beginning of the epidemic (April 2020), was considered by the government to be a prerequisite for an early reopening after the proactive lockdown of 11 March 2020. The system was continuously expanded throughout the pandemic (4). Rapid antigen-tests were introduced in April 2021. PCR-tests and rapid antigen-tests were available to all whether symptomatic or not and without needing a referral. The main goal in Denmark was to reduce the spread of SARS-CoV-2, protect vulnerable individuals such as nursing home residents and hospitalized patients, avoid overloading the healthcare system and keep society open to the largest possible extent. The test strategy was an important tool to identify infected individuals including non-symptomatic individuals, thereby reducing the spread of SARS-CoV-2 by initiating isolation, and contact tracing.

The national SARS-CoV-2 test system also turned out to be a critical source of data for surveillance and epidemiological analysis of the epidemic, including vaccine effectiveness analyses. For these reasons, and to inform future decisions on test strategies, it is important to describe the system and understand how test results reflect the underlying population. In this paper we provide a description of the set-up of the Danish national SARS-CoV-2 test system and analyse differences in PCR-testing patterns per demographic group and time period in relation to the three main waves of SARS-CoV-2 transmission which occurred in Denmark.

## Methods

### *Description of the development of the Danish national SARS-CoV-2 test system*

Denmark, a Scandinavian country of 5.86 million inhabitants, choose a two-pronged approach to testing for SARS-CoV-2, where testing was organized in two tracks, the so-called ‘healthcare’ and ‘community’ tracks (5). The healthcare track analysed all samples in the first months of the epidemic and then took a clinical approach with both in- and out-patients tested based on medical referrals, screening before hospitalization, outpatient visits at hospitals or at general practitioners as well as regular screening of healthcare staff. The samples from the healthcare track were analysed by the 10 clinical microbiology laboratories that exist in Denmark, within the regional hospitals, usually around the clock for hospital patients. During 2020, capacity was greatly increased by new instruments and expansion of the staff, the laboratories were mandated to be able to analyse up to 30,000 samples a day.

The second track, the community track, was established in addition to the healthcare track to provide readily available, free-of-charge testing in the local community, on-demand and without referrals. The community track, became responsible for more than 80% of the tests and its set-up is briefly summarised below. More information, including description of the laboratory procedures and detection of viral variants is found in the Supplementary Material.

Laboratory activities in the community track were centralized and conducted at Statens Serum Institut (SSI), the Danish national institute for infectious disease control which operates under the authority of the Ministry of Health. In April 2020, a high capacity, highly automated laboratory (TestCenter Denmark) was established at SSI in order to handle the large influx of samples. During the pandemic, the laboratory capacity reached 200.000 daily PCR-tests; the mandated performance requirement was that test results for 80% were reported within 24 hours. Oropharyngeal swabs for PCR-testing were taken by trained professionals in a network of testing stations that were established during the pandemic. When operating

at full capacity, people had a maximum of 20 km distance from their home to the nearest testing station as per government requirements.

# *Data logistics*

The testing stations of the community track used a centralized on-line booking system allowing users to book an appointment at any testing station via a single webpage. When booking on-line, users were identified via the existing “NemID” system, which is an app-based all-purpose, compulsory, national electronic identification system consisting of a user ID, a password and a (electronic) code card. Drop-in testing was sometimes available, subject to the demand for testing. All samples were registered electronically using bar code scanning in conjunction with sampling and without paper forms. All samples were registered via WebReq, which is a national online system for medical sample registration (5). Users were identified by scanning their healthcare ID card. Samples were registered by scanning the 2D barcode on the bottom of the matrix tube (a tube originally used for biobanking and not routine microbiology testing; in the healthcare track tubes were labelled with a unique national sample number). Thus, all sample registration was performed electronically with no manual data entry. All order data was transferred to a database at either SSI for the community track or the hospital laboratory for the healthcare track and was used to match laboratory results with patient data.

All test results were registered on the individual, using the Danish unique personal identification number, which is used in all national registries, enabling individual-level linkages between registries (6). Results were, depending on the requestor, reported electronically to either the patient’s GP or the hospitals electronic patient record and at the same time sent to and registered in the Danish Microbiology Database (MiBa) enabling real-time epidemiological surveillance throughout the epidemic (5). The SARS-CoV-2 results in MiBa were captured by an online service that allowed individuals to see their own test results via various existing public web-based health interfaces (e.g. [www.sundhed.dk](http://www.sundhed.dk)) and mobile apps.

Upon completed test, the user would receive an SMS or push-up notice, advising the user to log in and see the result. Users that tested positive for variants of concern could then be contacted directly via telephone by the contact tracing group of the Danish Patient Safety Authority.

### *Rapid antigen-testing*

From February 2021 rapid antigen-test also became part of the Danish community test system. It was funded by the Government, relied on test stations, and the public national data infrastructure. Thus, for public rapid antigen-testing, all test data and results were electronically traceable and thus available to the users, the medical system and for surveillance. A variety of assays were used for rapid antigen-testing, which was performed by several private companies on government contracts offering their services at testing stations throughout the country. Individuals who received a positive antigen-test result were advised to have it confirmed with a PCR-test in the community track, which also allowed positive samples to undergo WGS.

### *Data for the analyses of this paper*

The data analysis study presented in this paper was designed as a nationwide register-based cohort study, i.e., with the entire Danish population as cohort members. PCR-tests from both the community track and the healthcare track were included. The proportion of total PCR-test performed was 83.4% and 16.6% in the community and healthcare track, respectively.

Information on date of birth, sex, heritage, vital status, emigration and current residence municipality were obtained from the Danish Civil Registration System (CRS) (6). Information on vital status and emigration status were used for censoring in the Poisson regression models. Information on all positive, negative and inconclusive PCR-tests and rapid antigen-tests performed by the healthcare track and the

society track were obtained from MiBa (5). Information on administrated COVID-19 vaccines was obtained from the Danish Vaccination Registry (7).

The study population included all residents in Denmark aged 2 years or above (all residents eligible for SARS-CoV-2 tests). The study period was February 27, 2020 to March 10, 2022, i.e. from the first diagnosed case in Denmark until the official end of the period during which testing without medical indication was broadly available. The study consists of two descriptive analyses. The first descriptive analysis provides characteristics of individuals tested ‘never’, ‘rarely’, ‘commonly’ and ‘often’, stratified by PCR and rapid antigen-tests. The second descriptive analysis provides characteristics of PCR-tested individuals in three sub-periods to account for variation in test capacity and the emergence of new SARS-CoV-2 variants in each period: The periods were defined according to implementation and lifting of restrictions. Period I was from the first positive PCR-test in Denmark until the start of the second lockdown (February 27, 2020 to December 16, 2020). Period II was from the start of the second lockdown until all restrictions were lifted (December 17, 2020 to September 30, 2021); this period corresponds also broadly speaking to the time when vaccines were rolled out. Period III spanned from the reintroduction of restrictions until the implementation of guidelines (8) advising that PCR-testing be done only if symptomatic or at increased risk of a serious course of COVID-19 (November 11, 2021 to March 10, 2022), effectively ending the mass-testing period. We used Poisson regression to provide an incidence rate ratio (IRR) including a 95% confidence interval (CI), for being PCR-tested by sex, age groups, vaccination status, infection status, heritage and type of area. For this analysis, antigen-tests were excluded since during the epidemic, the PCR-test results were the primary basis for surveillance and since PCR-tests have been primarily utilized in epidemiological studies.

### *Statistical analysis*

Characteristics of individuals that were tested ‘never’, ‘rarely’, ‘commonly’ or ‘often’ were described using proportions. For both PCR-tests and rapid antigen-tests, individuals were categorized as ‘never tested’ if they had 0 tests, ‘rarely’ if they had 1-3 tests, ‘commonly’ if they had 4-15 tests and ‘often’ if they had more than 15 tests performed during the entire study period. Rarely, commonly and often were defined by quartiles of number of PCR-test by individuals with one or more PCR-tests. Characteristics of individuals PCR-tested in Period I, II and III were described using number of tested individuals and proportion tested individuals. The included characteristics were sex (female/male), age group at start of study period (10 levels: 2-9 years, 10-19 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, 80-89 years and 90+ years), heritage (four levels: Danish, non-western, western and unknown) and type of area (six levels: capital municipalities, commuter municipalities, metropolitan municipalities, provincial municipalities, rural municipalities and unknown). The definitions of Heritage and type of area were according to Statistics Denmark (9). The Heritage definition is presented in Supplementary (S1 Table).

Crude and adjusted IRR were calculated using Poisson regression models for each of the three periods. The adjusted Poisson regression models were adjusted for the variables above defined, i.e.: age group, sex, vaccination status, SARS-CoV-2 infection status (no infection/previous infected), heritage, and type of area. Individuals were defined as previous infected if they were registered with a positive PCR-test in MiBa otherwise they were defined as not infected. Vaccination status and infection status were included as time-varying covariates in the regression model by splitting time using Lexis expansion. However, for Period I, vaccination status was not analysed as the vaccination program had not yet been initiated. Only the covariate heritage had missing values. The missing values were categorized as unknown and included in analyses.



## Results

Between February 27, 2020 and March 10, 2022, there were in total 6,089,618 million residents in the Danish population of which 5,831,730 were 2 years or above at the start of this period. During this period, a total of 63.7 million PCR-tests and 60.0 million rapid antigen-tests were registered. The median number of PCR-tests and rapid antigen-tests done per individual was 7. Of the 5,831,730 individuals, 8.9% were never PCR-tested while 20.8% were never rapid antigen-tested. Among those often PCR-tested, the proportion of males was lower compared to females. The proportion of often PCR-tested was 29.9% and 19.0% among females and men, respectively. The proportion of never PCR-tested was 7.2% and 17.0% among individuals vaccinated and not vaccinated during the study period, respectively (Table 1). Furthermore, the proportion of never PCR or antigen-tested were higher among the oldest age groups compared to the youngest age groups (Table 1).

**Table 1. Characteristics of 5,831,730 individuals tested by PCR test or rapid antigen test, by group of test frequency, categorised as: never, rarely, commonly and often, Denmark, 2020-2022.**

	PCR tested				Rapid antigen tested			
	Never (%) 0 test	Rarely (%) 1-3 test	Commonly (%) 4-15 test	Often (%) >15 test	Never (%) 0 test	Rarely (%) 1-3 test	Commonly (%) 4-15 test	Often (%) >15 test
<b>Total</b>	8.9	20.2	47.4	23.5	20.8	18.7	34.4	26.0
<b>Sex</b>								
Female	8.1	18.1	45.9	27.9	20.9	18.3	33.6	27.2
Male	9.7	22.3	48.9	19.0	20.8	50.8	35.3	47.5
<b>Age groups (years)</b>								
2-9	4.1	17.7	62.3	15.8	34.4	10.8	34.4	2.5
10-19	2.5	12.1	59.8	25.5	3.6	5.6	25.4	65.4
20-29	7.7	16.5	50.5	25.3	9.4	8.1	37.4	23.6
30-39	6.0	14.7	47.7	31.5	10.7	14.5	42.4	32.3
40-49	5.6	14.8	44.6	35.0	11.9	12.1	42.4	14.5
50-59	7.7	18.9	42.7	30.7	18.3	22.4	40.8	18.5
60-69	13.0	27.1	43.1	16.8	28.6	17.3	34.9	3.5
70-79	19.6	36.7	38.3	5.4	40.7	33.0	24.2	2.2
80-89	25.8	39.6	29.9	4.7	70.4	4.7	6.6	0.0
≥90	28.1	34.2	29.6	8.1	93.0	6.3	0.7	0.0
<b>Vaccinated with ≥2 doses before March 10 2022</b>								
Yes	7.2	19.3	47.5	26.0	17.5	19.0	35.9	27.6
No	17.0	24.7	47.2	11.0	37.0	15.8	27.1	12.2

Heritage								
Danish	7.6	19.3	47.7	25.4	19.8	81.5	34.6	85.0
Non-west	8.9	23.5	52.7	14.9	17.6	21.1	37.4	23.9
West	16.1	23.0	43.5	17.4	22.6	7.5	34.4	6.4
Unknown	48.3	36.2	15.0	0.5	92.1	4.8	2.6	0.4
Type of area (municipality)								
Capital Municipalities	8.0	16.8	49.3	25.9	19.3	16.5	34.7	29.5
Commuter Municipalities	9.7	22.7	46.8	20.8	21.3	17.3	35.3	14.4
Metropolitan Municipalities	8.4	19.0	47.9	24.7	18.8	17.4	33.9	30.0
Provincial Municipalities	8.9	20.9	47.0	23.3	21.7	24.1	34.4	21.1
Rural Municipalities	9.9	23.0	45.5	21.6	23.0	20.3	33.6	23.1

173

174 The number of daily samples increased throughout the pandemic from a few thousand to a maximum  
175 of over 200,000 in the community track and 30,000 in the healthcare track. The number of PCR-tests  
176 peaked in December 2021 and January 2022, while the number of rapid antigen-tests peaked in May and  
177 June 2021; the highest number of daily PCR and rapid antigen-tests were 270,248 and 544,361, respectively  
178 (Figure 1). The number of PCR-test stations in use also varied over the study period, with a median of 268  
179 available PCR-test stations. During 2020, the number of test stations increased from 18 to 250. The highest  
180 number were available between March and June 2021, and between December 2021 and February 2022  
181 (Figure 2).

182 Figure 1. Number of performed PCR tests (dark blue) and rapid antigen tests (blue) by sample date,  
183 February 27, 2020 to March 10, 2022

184 Figure 2. Active PCR test stations in Denmark by year and ISO week. A test station was included as active if  
185  $\geq 1$  test performed was registered.

186

187 The proportion of individuals PCR-tested at least once was 63.1% in Period I, but higher in Period II  
188 (76.6%) and III (78.0%) although the opportunity to be rapid antigen-tested also existed in these periods. In  
189 all three periods, females, younger age groups and individuals from municipalities in the capital area were  
190 more likely to get PCR-tested (Table 2). Especially the older age groups were less likely to get PCR-tested in

191 Period II and III compared to Period I. Among individuals aged 70-79, 47.9% were PCR-tested in Period I  
192 compared to 57.8% and 55.1% which were PCR-tested in Period II and III, respectively (Table 2).

193 **Table 2. Characteristics of all individuals tested by RT-PCR in Denmark in the three waves**

	February 27, 2020 to December 16, 2020 (N-tests 9,006,261)		December 17, 2020 to September 30, 2021 (N-tests 32,484,654)		November 11, 2021 to March 10, 2022 (N-tests 19,421,685)	
	Number of tested individuals	Percentage tested	Number of tested individuals	Percentage tested	Number of tested individuals	Percentage tested
<b>Sex</b>						
Female	1,928,783	66.9	2,274,409	78.7	2,310,337	79.9
Male	1,730,457	60.7	2,130,411	74.5	2,171,062	76.0
<b>Age groups (years)</b>						
2-9	278,057	56.5	353,434	72.2	422,838	86.7
10-19	525,977	76.5	591,592	86.2	617,121	91.0
20-29	572,440	71.7	669,383	83.9	646,556	81.9
30-39	487,740	70.4	591,400	84.4	603,532	85.0
40-49	522,698	68.9	629,392	83.6	632,747	85.7
50-59	511,565	63.7	638,289	79.5	639,698	79.4
60-69	369,607	55.6	470,170	70.4	465,568	69.2
70-79	270,815	47.9	331,392	57.8	319,095	55.1
80-89	100,609	44.3	108,995	46.4	112,025	46.1
≥90	19,732	45.0	20,773	46.7	22,219	49.8
<b>Vaccinated with ≥2 doses before March 10 2022</b>						
Yes	3,158,071	65.9	3,774,898	78.4	3,754,205	78.5
No	501,169	53.2	629,922	67.2	727,194	75.3
<b>Heritage</b>						
Danish	3,085,149	64.5	3,707,642	77.0	3,801,913	79.0
Non-west	329,324	63.3	410,981	77.5	400,936	74.7
West	221,954	59.4	278,242	71.3	277,353	70.2
Unknown	22,813	40.2	7,955	52.6	1,197	51.5
<b>Type of area (municipality)</b>						
Capital	1,122,019	69.5	1,306,016	80.4	1,293,771	79.5

Municipalities						
Commuter Municipalities	511,395	57.5	656,050	73.7	676,580	76.2
Metropolitan Municipalities	514,451	65.8	620,260	79.0	619,941	78.8
Provincial Municipalities	785,723	60.7	984,584	75.9	1,013,578	78.2
Rural Municipalities	725,652	62.9	837,910	72.6	877,529	76.3
Unknown	1,928,783	66.9	2,274,409	78.7	2,310,337	79.9

194

195        The estimates from the adjusted Poisson regression models showed that throughout the study period,  
196        males were less likely to be PCR-tested, (IRR: 0.77) compared to females (Table 3). Also, over both Periods I,  
197        II and III, individuals with non-Danish heritage had relatively lower test rates. In period I (i.e., most of 2020),  
198        individuals aged 2-9 years and the oldest age groups were least likely to be PCR-tested compared to  
199        individuals aged 10-49 years. After SARS-CoV-2 infection, individuals had almost three times the test rate  
200        compared to those without a previous SARS-CoV-2 infection, different from in Periods II and III. Residents  
201        of commuter municipalities had the lowest IRR of being PCR-tested (IRR: 0.68) compared to capital  
202        municipalities (Table 3).

203

204 **Table 3. Unadjusted and adjusted IRR for PCR testing by sex, age, vaccination status, infection status, heritage and type of area in two study**  
 205 **periods**

	February 27, 2020 to December 16, 2020 (Period I)				December 17, 2020 to September 30, 2021 (Period II)				November 11, 2021 to March 10, 2022 (Period III)			
Sex	Number of tests	PYRS	Unadjusted IRR (95% CI)	Adjusted* IRR (95% CI)	Number of tests	PYRS	Unadjusted IRR (95% CI)	Adjusted* IRR (95% CI)	Number of tests	PYRS	Unadjusted IRR (95% CI)	Adjusted* IRR (95% CI)
Female	4,920,688	2,286,433	Reference	Reference	13,530,088	2,207,135	Reference	Reference	10,637,259	929,959	Reference	Reference
Male	3,846,754	2,260,054	0.79 (0.79-0.79)	0.78 (0.78-0.78)	17,779,026	2,177,791	0.77 (0.77-0.77)	0.74 (0.74-0.74)	8,050,190	919,373	0.77 (0.76-0.77)	0.75 (0.75-0.75)
<b>Age groups (years)</b>												
2-9	542,436	392,514	0.58 (0.58-0.58)	0.57 (0.57-0.57)	1,514,471	381,013	0.55 (0.55-0.55)	0.51 (0.51-0.51)	1,784,059	158,609	1.01 (1.01-1.01)	1.11 (1.11-1.11)
10-19	1,306,173	547,509	Reference	Reference	3,863,057	532,821	Reference	Reference	2,457,315	220,289	Reference	Reference
20-29	1,460,429	624,130	0.98 (0.98-0.98)	0.95 (0.95-0.95)	4,902,429	599,673	2.06 (2.05-2.06)	1.16 (1.16-1.16)	2,440,136	252,030	0.87 (0.86-0.87)	0.86 (0.85-0.86)
30-39	1,228,660	548,602	0.94 (0.94-0.94)	0.92 (0.92-0.92)	4,889,405	540,595	2.28 (2.27-2.28)	1.31 (1.31-1.32)	2,738,872	230,466	1.07 (1.07-1.07)	1.06 (1.06-1.06)
40-49	1,330,749	605,485	0.92 (0.92-0.92)	0.91 (0.91-0.91)	5,848,433	586,366	2.51 (2.50-2.51)	1.50 (1.50-1.50)	3,192,933	240,321	1.19 (1.19-1.19)	1.12 (1.11-1.12)
50-59	1,266,402	641,082	0.83 (0.83-0.83)	0.83 (0.82-0.83)	5,781,817	624,257	2.33 (2.33-2.33)	1.43 (1.43-1.44)	3,031,860	261,455	1.04 (1.04-1.04)	0.94 (0.94-0.94)
60-69	816,853	530,159	0.65 (0.64-0.65)	0.64 (0.64-0.65)	3,121,319	513,261	1.53 (1.53-1.53)	0.98 (0.98-0.98)	1,826,798	216,976	0.76 (0.75-0.76)	0.66 (0.66-0.67)
70-79	542,323	448,602	0.51 (0.51-0.51)	0.50 (0.50-0.50)	1,117,676	427,399	0.66 (0.66-0.66)	0.46 (0.46-0.46)	840,287	184,129	0.42 (0.42-0.42)	0.36 (0.36-0.36)
80-89	222,524	176,300	0.53 (0.53-0.53)	0.51 (0.51-0.51)	236,573	157,577	0.38 (0.38-0.38)	0.32 (0.32-0.33)	294,989	73,442	0.40 (0.40-0.40)	0.33 (0.33-0.33)
≥90	50,893	32,105	0.66 (0.66-0.67)	0.61 (0.60-0.61)	33,934	21,964	0.39 (0.38-0.39)	0.40 (0.40-0.41)	80,200	11,616	0.72 (0.73-0.73)	0.58 (0.58-0.58)
<b>Vaccination status</b>												
Unvaccinated or first vaccine dose	-	-	-	-	27,261,375	3,252,360	Reference	Reference	3,488,136	362,528	Reference	Reference
Second vaccine dose	-	-	-	-	4,042,478	1,130,643	0.43 (0.43-0.43)	0.44 (0.44-0.44)	7,181,130	677,356	1.10 (1.10-1.10)	1.16 (1.16-1.16)
Third vaccine dose	-	-	-	-	-	-	-	-	8,018,183	809,448	1.03 (1.03-1.03)	1.28 (1.28-1.28)
<b>SARS-CoV-2 infection status</b>												
No infection	8,725,239	4,539,788	Reference	Reference	30,737,893	4,317,792	Reference	Reference	17,339,226	1,696,155	Reference	Reference

Previous infected	42,203	6,699	3.28 (3.25-3.31)	2.97 (2.94-3.00)	977,293	147,645	0.93 (0.93-0.93)	0.92 (0.92-0.92)	1,507,326	166,786	0.88 (0.88-0.89)	0.85 (0.85-0.85)
<b>Heritage</b>												
Danish	7,376,879	3,831,332	Reference	Reference	27,354,547	3,699,544	Reference	Reference	16,309,738	1,550,717	Reference	Reference
Non-western	807,877	410,424	1.02 (1.02-1.02)	0.87 (0.87-0.88)	2,220,577	405,543	0.74 (0.74-0.74)	0.61 (0.61-0.61)	1,361,216	174,354	0.74 (0.74-0.74)	0.70 (0.70-0.70)
Western	535,505	287,165	0.97 (0.97-0.97)	0.85 (0.85-0.86)	1,731,056	279,085	0.84 (0.84-0.84)	0.71 (0.71-0.71)	1,014,460	123,948	0.78 (0.78-0.78)	0.74 (0.74-0.74)
Unknown	47,181	17,566	1.39 (1.38-1.41)	1.47 (1.45-1.48)	2,934	755	0.53 (0.51-0.55)	0.55 (0.54-0.58)	2,035	314	0.61 (0.58-0.63)	0.72 (0.69-0.75)
<b>Type of area (municipality)</b>												
Capital Municipalities	3,038,856	1,274,925	Reference	Reference	9,034,268	1,199,828	Reference	Reference	5,231,891	508,849	Reference	Reference
Commuter Municipalities	1,116,671	706,702	0.66 (0.66-0.66)	0.68 (0.68-0.68)	4,685,760	713,111	0.87 (0.87-0.87)	0.87 (0.86-0.87)	2,902,934	299,810	0.94 (0.94-0.94)	0.92 (0.92-0.92)
Metropolitan Municipalities	1,234,705	619,498	0.84 (0.83-0.84)	0.83 (0.83-0.83)	4,572,545	584,038	1.04 (1.04-1.04)	1.02 (1.02-1.02)	2,405,581	246,445	0.95 (0.95-0.95)	0.93 (0.93-0.93)
Provincial Municipalities	1,776,660	1,028,573	0.72 (0.72-0.73)	0.74 (0.73-0.74)	7,212,321	1,009,919	0.95 (0.95-0.95)	0.94 (0.94-0.94)	4,378,317	425,138	1.00 (1.00-1.00)	0.98 (0.98-0.98)
Rural Municipalities	1,600,550	916,790	0.73 (0.73-0.73)	0.76 (0.76-0.76)	5,804,220	878,031	0.88 (0.88-0.88)	0.88 (0.88-0.89)	3,768,726	369,091	0.99 (0.99-0.99)	1.00 (1.00-1.00)

206 \*Adjusted for age group, sex, vaccination status, SARS-CoV-2 infection status, heritage, and type of area

In Period II (December 17, 2020 to September 30, 2021), again senior individuals were less likely to be PCR-tested compared to the reference group of individuals aged 10-19 years, while individuals in the age groups from 20-69 had higher IRR's. The highest IRR was observed among individuals aged 40-49 years (IRR: 2.51). After their second COVID-19 vaccine dose, individuals had 0.44 times the rate of being tested compared to individuals with no or one COVID-19 vaccine dose. After SARS-CoV-2 infection, individuals had 0.92 times the test rate compared to those without a previous SARS-CoV-2 infection. In addition, residents of commuter, provincial and rural municipalities had reduced IRR's, ranging between 0.88 and 0.94 compared to capital municipalities (Table 3).

In Period III (November 11, 2021 to March 10, 2022), all age groups had lower adjusted IRR's for being PCR-tested compared to individuals aged 10-19 years, except for individuals aged 30-39 years and 40-49 years. (IRR: 1.06 and IRR: 1.12, respectively). Similar to Period II, it was the three older age groups, which were less likely to be PCR-tested. However, in Period III, individuals vaccinated with two or three COVID-19 vaccine doses were more likely to be PCR-tested compared to individuals who received none or one COVID-19 vaccine dose. For individuals vaccinated with two or three doses the IRR was 1.16 and 1.28, respectively. Individuals with a previous SARS-CoV-2 infection were less likely to be PCR-tested (Table 3).

The results of the sub-analysis including only PCR-tests from the community track, showed the same associations as the main analysis. However, the older age groups were PCR-tested even less in the community track compared to when the community and the healthcare track was analysed as a group (S2 Table).

## Discussion

This study contributes important insight into how the Danish national SARS-CoV-2 test system functioned and how it was received by the population. A total of 63.7 million PCR-tests and 60.0 million rapid antigen-tests were performed between February 27, 2020 and March 10, 2022. We show that a high proportion (91.1%) of the Danish population was PCR-tested at least one time during this period. Although the test system was used by all demographic groups, female sex, younger age, Danish heritage and living in the capital area were all factors positively associated with PCR-testing. The association between COVID-19 vaccination and PCR-testing changed from negative to positive over time. Furthermore, the association between previous infection and PCR-testing changed from positive in Period I to negative in Periods II and III. The lower test frequency among the oldest age groups may possibly be explained by the older population either isolating or finding it difficult to use the digital test booking system or having difficulties transporting themselves to a test station. The high test-frequency among children is likely associated with this group being more often unvaccinated. Vaccination was not offered before the age of 6 years and overall vaccination coverage among individuals younger than 16 years was 37%, less than for adults (86%), by end of study. The fact that persons with recent immigration background had lower test rates is interesting; it might in part be due to language barriers or perhaps with a tendency to be disenfranchised and less likely to follow government guidelines.

In the study period between December 17, 2020 and September 30, 2021, people vaccinated with two COVID-19 vaccine doses were less likely to be PCR-tested compared to those given none or just a single COVID-19 vaccine dose (IRR: 0.44). However, in the study period between November 11, 2021 and March 10, 2022, those vaccinated with two or three COVID-19 vaccine doses were more often PCR-tested despite public health authorities having encouraged more frequent testing for the unvaccinated. Compared to those given none or just a single COVID-19 vaccine dose, the IRR was 1.16 and 1.28 for two and three vaccine doses, respectively. The Omicron SARS-CoV-2 variant was circulating in this period and it was known that vaccine effectiveness was lower against this variant (10). This might explain why individuals



were tested regardless of their vaccination status. Furthermore, the unvaccinated group changes over time and between the two periods. Unvaccinated people may have been engaging less with the health care system overall, especially in Period III where all individuals were offered vaccination.

Denmark performed more tests per inhabitants than other comparable countries. To illustrate, between February 27, 2020 and March 10, 2022, the mean number of PCR-tests per day per thousand persons was 14.4 in Denmark, 3.0 in Sweden, 2.8 in Norway, 9.6 in the UK and 2.4 in the Netherlands (3). The Danish national SARS-CoV-2 test system represented a huge infrastructure investment, but also proved very valuable for surveillance and control of the epidemic. Testing as many individuals as possible, tracking infected individuals, and tracing their contacts was deemed in Denmark as an effective strategy to reduce the spread of the virus. Timely and detailed surveillance data provided a foundation for risk assessments that informed public health regulations and thus decisions on restrictions such as mask mandates and launch or release of lockdowns could be made on a foundation of scientific facts. Daily geographic detailed summary results from the tests was made publicly available via web-based dashboards that were shared with stakeholders and widely reported in the press. This rapid and open publication of surveillance data was likely also an important factor in maintaining the population's confidence in the public health authorities.

The World Health Organization (WHO) stated that testing was a critical element to the overall prevention and control strategy for COVID-19 (11). The WHO recommends that all individuals meeting the case definition for COVID-19, irrespective of vaccination or disease history, be tested for SARS-CoV-2 (11). However, testing of asymptomatic individuals can be informative in instances such as follow up of contacts of confirmed or probable cases or testing of health care and long-term care facility workers that are frequently exposed (11). Notwithstanding, widespread testing of asymptomatic populations, including self-testing, is not recommended by the WHO, based on lack of evidence on impact and cost-effectiveness of such approaches and the concern that this approach risks diverting resources from higher priority testing

indications (11). Thus, the Danish test system thus goes beyond what WHO recommended. The available evidence of the effect of mass testing is sparse. A Swiss single-centre cohort study compared two testing strategies (restricted and extended strategy) (12). They concluded that widespread testing is crucial to understand and control the spread of infection, and to maximize identification of infected people. Access to free testing was found to be essential, not only to achieve infection control, but also to eliminate any discrimination between the different layers of society (12).

The Danish test system relied on several features/strengths that enabled the large-scale testing for SARS-CoV-2. The system leveraged on an existing infrastructure, including information and communication technologies, which facilitated the centralized and uniform lab set-up and the ability for users to safely log in and book test time slots and see the test results via computer/smartphone as well as the ability to individually link data on all residents in Denmark across the nationwide high-quality registries. The low turnaround times were also a strength as the rapid response made it possible for users to make informed decisions based on their test results, including mitigation of further spread of SARS-CoV-2. Another strength was that it was mandatory for providers performing SARS-CoV-2 testing to report electronically to MiBa (5). A limitation was that rapid antigen self-tests for SARS-CoV-2 infection were not included in the national surveillance. However, self-tests were introduced into Denmark late and played a smaller role than in many other countries due to the wide availability of PCR-tests and those testing positive by self-tests were advised to take a follow-up test in the national PCR-test system. Although we adjusted the Poisson regression models for potential confounders (sex, age, vaccination status, infection status, heritage and type of area), we cannot rule out that unmeasured confounders such as time varying COVID-19 guidelines, distance to test station, socioeconomic factors, and health behaviour may have affected the results. Further research should include qualitative research to examine barriers for PCR-testing. Furthermore, an assessment of the impact and the cost effectiveness of the system is beyond the scope of the present paper.

The ability to effectively track and trace variants of concern was considered valuable. For example, it was considered critical for an early and stepwise reopening of the Danish society in April 2020 and it also made it possible to delay community spread of the Delta variant by 10 weeks. This was of major importance as it provided sufficient time to vaccinate vulnerable groups thus mitigating the impact of the Delta variant.

Another benefit of the Danish testing infrastructure was its use for scientific studies. Because the test information was person-identifiable and linkage with national health and administrative registers were possible, the test-system also became a resource for epidemiological studies. The different use of the test system by vaccine status has implications for field studies of vaccine effectiveness. For example, a higher testing activity among vaccine recipients may lead to underestimating vaccine effectiveness since case ascertainment will increase in this group. Likewise, in the estimation of immunity following natural infections, different test behavior after a positive PCR will influence the outcome. The Danish test stations were also utilised to also conduct national sero-epidemiological study series (13). Moreover, the person-identifiable, centrally registered test data in combination with Danish health and administrative registers offering data-linkage, proved an important epidemiological data resource and was used for a large series of studies providing information, often of international value, during the epidemic. Subsequently, studies on population protection (14, 15), vaccine effectiveness (10, 16, 17), virulence of variants (18, 19), epidemical dynamics (20), long COVID (21) and forecasting and risks associated with vulnerable patient or community groups (22-26) were produced using the data from the study period. With the current paper, we hope to provide a further basis for such studies to come.

It should be recognised that testing patterns depend on factors besides the actual service provided. Throughout the pandemic various restrictions were implemented and lifted depending on the development of the pandemic and the developing understanding of the transmission of SARS-CoV-2 (27). During certain periods a negative PCR-test was necessary in order take part in civil life (e.g. access to sport/public institutions, restaurants, foreign travel). Further, staff at hospitals, nursing homes and home care have

actively been encouraged to be voluntarily tested at their workplace several times a week for prolonged periods. These recommendations and requirements definitely played a role in testing patterns but is beyond the scope of this study.

In conclusion, the results demonstrate that the extensive, free-of-charge, national SARS-CoV-2 test system in Denmark was well received by the majority of Danish population. However, demographic differences in the test uptake existed suggesting challenges to health equity in the society and possible biases in studies related to SARS-CoV-2. In the future, it might be relevant to focus on increasing the test uptake in individuals aged 70 years or above and unvaccinated individuals.

## Acknowledgements

We would like to thank the staff in all the test centers, at the ten Departments of Clinical Microbiology in Denmark, and at the many departments of the SSI taking part in setting up and running the test system (including the Virology Laboratory, TestCenter Denmark, Campus Services, the National Biobank, Infections Disease Epidemiology and Prevention, and the Data Integration and Analysis Secretariat). The authors thank Dr. Martin Collin Fjordholt for critical reading of the manuscript. Many structures in Danish society contributed to establishing and running the test centres, special contributions were given by the Novo Nordic Foundation (Grant number: NNF20SA0063854), Novo Nordisk Denmark (providing staff), McKinsey (sourcing) and the Danish Military (logistical support).

## Ethics approval

This article only contains aggregated results and no personal data. For this reason, consent was not needed and not obtained. Further, according to Danish law, ethical approval should not be obtained for anonymized aggregated register-based studies not using biological material (cf. implementing decree, act no. 1338 of 2020-09-01 on research ethics review of health research projects). For the same reasons, the article is not covered by the European General Data Protection Regulation. This work was carried out under the Surveillance auspices of the SSI as regulated in paragraph 222 of the Danish Communicable Disease Act and was therefore not listed with the Danish Data Protection Agency.

## References

1. Giri B, Pandey S, Shrestha R, Pokharel K, Ligler FS, Neupane BB. Review of analytical performance of COVID-19 detection methods. *Anal Bioanal Chem*. 2021;413(1):35-48.
2. Cheng MP, Papenburg J, Desjardins M, Kanjilal S, Quach C, Libman M, et al. Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus 2: A Narrative Review. *Ann Intern Med*. 2020;172(11):726-34.
3. Hannah Ritchie EM, Lucas Rod s-Guirao, Cameron Appel, Charlie Giattino, Esteban Ortiz-Ospina, Joe Hasell, Bobbie Macdonald, Saloni Dattani and Max Roser. Coronavirus (COVID-19) Testing: Our World in Data; [Available from: <https://ourworldindata.org/coronavirus-testing>.
4. COVID-19: Test strategy: The Danish Health Authority and the Ministry of Justice; 2021 [cited 2022 April 4]. Available from: [https://sum.dk/Media/E/2/COVID-19\\_Teststrategi\\_250321.pdf](https://sum.dk/Media/E/2/COVID-19_Teststrategi_250321.pdf).
5. Sch nning K, Dessau RB, Jensen TG, Thorsen NM, Wiuff C, Nielsen L, et al. Electronic reporting of diagnostic laboratory test results from all healthcare sectors is a cornerstone of national preparedness and control of COVID-19 in Denmark. *Apmis*. 2021;129(7):438-51.
6. Schmidt M, Pedersen L, S rensen HT. The Danish Civil Registration System as a tool in epidemiology. *Eur J Epidemiol*. 2014;29(8):541-9.
7. Grove Krause T, Jakobsen S, Haarh M, M lbak K. The Danish vaccination register. *Euro Surveill*. 2012;17(17).
8. On being tested: Danish Health Authority; [cited 2022 October 12]. Available from: [https://www.sst.dk/en/English/Corona-eng/Symptoms\\_tested-positive-or-a-close-contact/On-being-tested](https://www.sst.dk/en/English/Corona-eng/Symptoms_tested-positive-or-a-close-contact/On-being-tested).
9. : Danish Covid-19 Genome Consortium; [Available from: <https://www.covid19genomics.dk/>.
10. Gram MA, Emborg HD, Schelde AB, Friis NU, Nielsen KF, Moustsen-Helms IR, et al. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study. *PLoS Med*. 2022;19(9):e1003992.

11. Recommendations for national SARS-CoV-2 testing strategies and diagnostic capacities: World Health Organization; 2021 [cited 2022 October 12]. Available from: <https://www.who.int/publications/i/item/WHO-2019-nCoV-lab-testing-2021.1-eng>.
12. Baggio S, Spechbach H, Vernaz N, Guessous I, Gétaz L, Kaiser L, et al. SARS-CoV-2 testing strategy: A comparison of restricted and extended strategies in a Swiss outpatient cohort from the community and hospital employees. *PLoS One*. 2021;16(4):e0250021.
13. Espenhain L, Tribler S, Sværke Jørgensen C, Holm Hansen C, Wolff Sönksen U, Ethelberg S. Prevalence of SARS-CoV-2 antibodies in Denmark: nationwide, population-based seroepidemiological study. *Eur J Epidemiol*. 2021;36(7):715-25.
14. Hansen CH, Michlmayr D, Gubbels SM, Mølbak K, Ethelberg S. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. *The Lancet*. 2021;397(10280):1204-12.
15. Michlmayr D, Hansen CH, Gubbels SM, Valentiner-Branth P, Bager P, Obel N, et al. Observed protection against SARS-CoV-2 reinfection following a primary infection: A Danish cohort study among unvaccinated using two years of nationwide PCR-test data. *Lancet Reg Health Eur*. 2022;20:100452.
16. Gram MA, Nielsen J, Schelde AB, Nielsen KF, Moustsen-Helms IR, Sørensen AKB, et al. Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study. *PLoS Med*. 2021;18(12):e1003874.
17. Nielsen KF, Moustsen-Helms IR, Schelde AB, Gram MA, Emborg HD, Nielsen J, et al. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study. *PLoS Med*. 2022;19(11):e1004037.
18. Lyngse FP, Kirkeby CT, Denwood M, Christiansen LE, Mølbak K, Møller CH, et al. Household transmission of SARS-CoV-2 Omicron variant of concern subvariants BA.1 and BA.2 in Denmark. *Nat Commun*. 2022;13(1):5760.

19. Lyngse FP, Mortensen LH, Denwood MJ, Christiansen LE, Møller CH, Skov RL, et al. Household transmission of the SARS-CoV-2 Omicron variant in Denmark. *Nat Commun.* 2022;13(1):5573.
20. Espenhain L, Funk T, Overvad M, Edslev SM, Fonager J, Ingham AC, et al. Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, December 2021. *Euro Surveill.* 2021;26(50).
21. Sørensen AIV, Spiliopoulos L, Bager P, Nielsen NM, Hansen JV, Koch A, et al. A nationwide questionnaire study of post-acute symptoms and health problems after SARS-CoV-2 infection in Denmark. *Nat Commun.* 2022;13(1):4213.
22. Hansen CH, Friis NU, Bager P, Stegger M, Fonager J, Fomsgaard A, et al. Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark. *Lancet Infect Dis.* 2022.
23. Bager P, Wohlfahrt J, Fonager J, Rasmussen M, Albertsen M, Michaelsen TY, et al. Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study. *Lancet Infect Dis.* 2021;21(11):1507-17.
24. Nilsson SF, Laursen TM, Osler M, Hjorthøj C, Benros ME, Ethelberg S, et al. Adverse SARS-CoV-2-associated outcomes among people experiencing social marginalisation and psychiatric vulnerability: A population-based cohort study among 4,4 million people. *Lancet Reg Health Eur.* 2022;20:100421.
25. Nilsson SF, Laursen TM, Osler M, Hjorthøj C, Benros ME, Ethelberg S, et al. Vaccination against SARS-CoV-2 infection among vulnerable and marginalised population groups in Denmark: A nationwide population-based study. *Lancet Reg Health Eur.* 2022;16:100355.
26. Overvad M, Koch A, Jespersen B, Gustafsson F, Krause TG, Hansen CH, et al. Outcomes following SARS-CoV-2 infection in individuals with and without solid organ transplantation-A Danish nationwide cohort study. *Am J Transplant.* 2022;22(11):2627-36.




27. Munch PK, Espenhain L, Hansen CH, Krause TG, Ethelberg S. Case-control study of activities associated with SARS-CoV-2 infection in an adult unvaccinated population and overview of societal COVID-19 epidemic counter measures in Denmark. PLoS One. 2022;17(11):e0268849.

## Supporting information captions

S1 Methods

S1 Table. Definition of heritage (as defined by Statistics Denmark)

S2 Table. Unadjusted and adjusted IRR for PCR testing in the community track by sex, age, vaccination status, infection status, heritage and type of area in three study periods



Active PCR-test stations

